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Purpose
Gastric cancer is the second leading cause of cancer-related death worldwide. Although
surgery is the standard curative treatment for gastric cancer, relapse occurs in a large num-
ber of patients, except in the case of early diagnosed gastric cancer. Following previous
studies that identified endoplasmic reticulum oxidoreductin 1- (ERO1L) as a potential
marker for gastric cancer, we investigated the functional role of ERO1L in gastric cancer.
Materials and Methods
For validation of microarray data, the mRNA expression level of ERO1L was measured by
quantitative real-time reverse transcription polymerase chain reaction in 56 independent
stage III gastric cancer patients. Immunohistochemical staining was performed to examine
the protein expression level of ERO1L in 231 gastric cancer patients. Correlation between
gene expression and cancer prognosis was evaluated.
Results
Patients with high ERO1L expression had poorer survival than those with low expression 
(p < 0.01). Functional assays demonstrated that ERO1L knockdown inhibited cell prolifer-
ation, migration, invasion, and chemoresistance. In addition, involvement of inactivation of
Akt and JNK signaling in molecular mechanisms of ERO1L inhibition was demonstrated. 
Conclusion
High expression of ERO1L is associated with poor prognosis of patients with gastric cancer.
These results indicate that ERO1L expression may be a clinically promising therapeutic tar-
get for prevention of gastric cancer.
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Introduction
Gastric cancer is the second leading cause of cancer-related
death worldwide [1]. Despite a decrease in the incidence of
gastric cancer in some developed countries over the past
decade, it is estimated that one million new cases are diag-
nosed each year. The clinical diversity of gastric cancer arises
from its diverse molecular biology [2,3], caused by changes
in the expression of various genes. Current chemotherapy-
based treatments for advanced gastric cancer do not demon-
strate a substantial effect on overall survival (OS) [4,5]. Thus,
identification of new, effective therapeutic approaches is of
great urgency [6-12].
Hypoxia, a state of reduced oxygen availability, is an 
important factor making tumors less responsive to radiation
and chemotherapy. Numerous studies have shown that 
hypoxic tumors have a more aggressive phenotype [13], thus,
tumor hypoxia correlates with a more aggressive disease
course and limits the effectiveness of anti-cancer therapies. 
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Endoplasmic reticulum oxidoreductin 1- (ERO1L) is a 
hypoxia-inducible endoplasmic reticulum–resident oxidase
that regulates the post-translational branch of oxidized pro-
tein folding [14,15]. Human ERO1L is expressed at a very low
level in normoxic cells. However, it has been shown that
ERO1L is induced in hypoxic cells in response to low oxygen
availability [15]. Interestingly, co-induction of ERO1L and
vascular endothelial growth factor (VEGF) in hypoxic tumor
cells suggests that ERO1L might be harnessed for reducing
levels of this key pro-angiogenic factor. Considering that 
hypoxia-induced secretion of VEGF plays a key role in tumor
angiogenesis, findings reported here suggest ERO1L as a 
potential anti-angiogenic target [16].
In this study, we further investigated the clinical signifi-
cance and functional role of ERO1L expression in gastric can-
cer. First, analysis of ERO1L expression in gastric cancer was
performed using quantitative real-time reverse transcription
polymerase chain reaction (qRT-PCR) and immunohisto-
chemical staining in gastric cancer patients. We also identi-
fied the relationship between ERO1L expression and
clinicopathological features and evaluated its prognostic
value in post-resection survival of gastric cancer patients. In
addition, we evaluated the functional role of ERO1L in gas-
tric cancer by examining the proliferation, migration, and 
invasion of gastric cell lines.
Materials and Methods
1. Patients and samples
Tumor specimens and clinical data were obtained from 
patients with primary gastric adenocarcinoma who under-
went curative gastrectomy as the primary treatment between
1999 and 2007 at Yonsei University, Severance Hospital
(Seoul, Korea), and Yonsei University, Gangnam Severance
Hospital (Seoul, Korea). Three patient groups were used for
each experiment: group 1 (65 gastric cancer patients under-
went curative surgery as a primary treatment) for microar-
ray; group 2 (56 formalin-fixed, paraffin-embedded tissue
from a separate gastric adenocarcinoma patient group) for
validation tests using qRT-PCR; and group 3 (paraffin-
embedded samples from 231 patients with gastric cancer) for
tissue microarray immunohistochemistry. All samples were
collected after obtaining written informed consent from 
patients, and the study was approved by the Institutional 
Review Board of Yonsei University, Gangnam Severance
Hospital (Seoul, Korea). 
2. Gene expression microarray data analysis
The previously generated gene expression data from gas-
tric cancer patients are available in NCBI’s GEO public data-
base (microarray data accession number, GSE13861) [12].
Sixty-five gastric cancer patients underwent curative surgery
as a primary treatment, with clinical data obtained from Yon-
sei University, Severance Hospital (Table 1). Sixty-five sur-
gically removed frozen gastric adenocarcinoma tissues and
19 normal surrounding tissue samples were used for the 
microarray experiments. Total RNA was extracted using a
mirVana RNA Isolation Labeling Kit (Ambion, Austin, TX).
For labeling and hybridization, 500 ng of total RNA was
used, according to the manufacturer’s protocols (Human-
HT12 v.3 Expression BeadChip, Illumina, San Diego, CA).
The microarray data were normalized using the quantile nor-
malization method in the Linear Models for Microarray Data
(LIMMA) package in the R language environment [17]. The
expression level of each gene was transformed into a log2
base before additional analysis was performed. The random
variance t test was applied for identification of differentially
expressed genes between the two tissue types. The differ-
ences in gene expression were considered significant if the
p-value was less than 0.001. Cluster analysis was performed
using Cluster 3.0 and TreeView24 [18]. Univariate analysis
was performed by dividing the patients into two groups
based on the median value of each gene expression level to
search for prognostic genes.
3. qRT-PCR and analysis
Stage III samples were chosen from 56 different gastric can-
cer patients for validation of the microarray data. Total RNA
was extracted according to the manufacturer’s instruction
manual (RecoverAll Total Nucleic Acid Isolation, Ambion).
ERO1L gene expression was assayed using qRT-PCR with
specific Taqman primers (Applied Biosystems, Foster City,
CA). Real-time reverse transcription polymerase chain reac-
tion (PCR) amplification was performed using the 7900HT
Fast Real-Time PCR System with a 384-well block module
(Applied Biosystems). Cycling conditions were 48°C for 30
minutes and 95°C for 10 minutes, followed by 40 cycles at
95°C for 15 seconds and 60°C for 60 seconds. Total RNA was
isolated from cultures of gastric cancer cells grown in 6-well
plates using TRIzol (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. cDNA was synthesized from 
1 µg of total RNA using a Maxima First Strand cDNA Syn-
thesis Kit (Thermo Scientific, Rockford, IL). Real-time quan-
titative PCR amplifications were performed by SYBR Green
assay on a 7500 Real-Time PCR System with 96-well block
module (Applied Biosystems). SYBR Green PCR conditions
were 50°C for 2 minutes and 95°C for 10 minutes, followed
by 95°C for 50 seconds, 60°C for 50 seconds, and 72°C for 1
minute for 40 cycles. SYBR Green Master Mix contains an 
internal passive dye, ROX, in addition to SYBR Green dye.
Relative amounts of mRNA were calculated from the thresh-
old cycle (CT) number based on expression of -2 microglob-
ulin or -actin as an endogenous control. All experiments
were triplicated and the values averaged.
4. Tissue microarray construction and immunohistochem-
ical staining
Paraffin-embedded tissue microarray blocks of gastric can-
cer tissue specimens were created from 231 patients. Each
block contained 3-mm cores of gastric cancer tissue. The 
4-µm-thick sections were deparaffinized and processed to
block endogenous peroxidase activity. Next, an antigen 
retrieval step was performed, and primary anti-ERO1L anti-
body (1:100, monoclonal, Abnova, Taipei, Taiwan) was sub-
sequently applied to the sections. The sections were then
incubated with a secondary antibody (HRP-mouse), and the
stains were developed using a Nova-RED Substrate Kit (Vec-
tor Laboratory, Burlingame, CA). The samples were then
counterstained with Harris hematoxylin. ERO1L protein 
expression levels were evaluated by two pathologists. The
staining intensity was recorded as score 0, negative; score 1,
weaker than normal; score 2, equally intense as normal; and
score 3, strong than normal. High-expression was defined as
a staining score  3 and low-expression as a staining score 
< 3. For slides heterogeneously stained within a tumor, we
graded the highest intensity within the tumor.
5. Cell culture and chemotherapeutic agents
Gastric cancer cell lines (AGS, SNU1, MKN1, MKN28,
MKN45, and NCI-N87) and human embryonic kidney cell
lines 293T (HEK 293T) were obtained from low-passage seed
stocks at the Korean Cell Line Bank (KCLB). Cells were 
exposed to hypoxia by placement in a mixed-gas incubator
infused with an atmosphere consisting of 94% N2, 5% CO2,
and 1% O2. Paclitaxel and 5-fluorouracil (5-FU) were dis-
solved in dimethylsulfoxide and sterile water, respectively.
All chemotherapeutic agents were obtained from Sigma-
Aldrich (St. Louis, MO).
6. Establishment of stable cell line
pGIPZ-shERO1L and pGIPZ-shNonTarget vectors were
purchased from Dharmacon (Dharmacon, Chicago, IL).
Table 1. Clinicopathological factors of gastric cancer patients
Characteristic Microarray (n=65) qRT-PCR (n=56) TMA (n=231)
Age
Mean (range, yr) 63 (32-83) 60 (28-76) 58 (25-77)
Sex
Male 46 (71) 31 (55) 144 (62) 
Female 19 (29) 25 (45) 87 (38)
Follow-up duration
Median (95% CI, mo) 41.7 (41-42) 83.8 (78.6-91.4) 95.9 (91.3-97.1)
Histological type
Intestinal 23 (35) 15 (27) 80 (35)
Diffuse 42 (65) 41 (73) 151 (65)
TNM stage
I 12 (18) 0 ( 92 (40)
II 11 (17) 0 ( 58 (25)
III 26 (40) 56 (100) 64 (28)
IV 16 (25) 0 ( 17 (7)
Location
Cardia 5 (8) 10 (18) 20 (9)
Non-cardia 60 (92) 46 (82) 211 (91)
Adjuvant chemotherapy
Yes 49 (75) 55 (98) 143 (62)
No 16 (25) 1 (2) 88 (38)
Values are presented as number (%) unless otherwise indicated. qRT-PCR, quantitative real-time reverse transcription poly-
merase chain reaction; TMA, tissue microarray; CI, confidence interval.
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pGIPZ-shERO1L and pGIPZ-shNonTarget lentiviral vectors
were transfected into HEK 293T cells in 60-mm dishes using
Fugene 6 (Promega, Madison, WI) according to the manufac-
turer’s protocol. Culture medium containing virus particles
was collected 48 hours later and added to gastric cancer cell
lines. Twenty-four hours later, transduced cells were selected
for 10 days with puromycin (Invitrogen).
7. Boyden chamber assay
After trypsinization, invasiveness of cells was tested in
vitro by Boyden chamber invasion assay (Neuro Probe 
48-well Micro Chemotaxis Chamber, Neuro Probe Inc.,
Gaithersburg, MD). Matrigel (BD Transduction Lab, San Jose,
CA) was diluted to 25 mg/50 µL with cold distilled water
and then applied to 8-µm pore size polycarbonate membrane
filters. Cells were seeded in the upper part of the Boyden
chamber at a density of 1105 cells/well in 50 µL of serum
free medium and then incubated for 24 hours at 37°C. 
The lower chamber also contained standard medium with
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Fig. 2. Two different conditions of gastric cancer cell lines,
normoxia and hypoxia, show mRNA expression patterns.
mRNA expression patterns of gastric cancer cells (AGS,
NCI-N87, and SNU1) in normoxia and hypoxia are 
depicted in a heat map. The color red or green reflects rel-
ative high or low expression level, respectively.
0.1% fetal bovine serum. Cells that invaded the lower surface
of the membranes were stained using a Diff-Quik Stain Kit
(Triangle Biochemical Sciences Inc., Durham, NC). Invading
cells in five randomly selected fields were counted using 
Microscope Axio Imager M2 (Carl Zeiss, Thornwood, NY).
To determine the effect of ERO1L on cell migration, cells
were seeded in a Boyden chamber on membrane filters not
coated with Matrigel. Migration of cells was measured as 
described in the invasion assay.
8. Cell viability assay and clonogenicity
Cell viability was determined using an EZ-Cytox Cell 
Viability Assay Kit (Daeil Lab Service Co., Seoul, Korea) 
according to the manufacturer's instructions. Briefly, 20 µL
of EZ-Cytox kit reagent was added to each well of a 96-well
microplate, followed by incubation at 37°C in a humidified
CO2 incubator for 2 hours. Optical density was then meas-
ured at a wavelength of 450 nm using a 96-well microplate
reader (Bio-Rad Laboratories Inc., Hercules, CA). The exper-
iment was performed in triplicate.
Cells were harvested and resuspended in complete growth
media. Cells were seeded onto 6-well plates (1103 cells/
well) and allowed to grow until visible colonies formed (21
days). Cell colonies were fixed with 10% methanol and 10%
acetic acid, stained with 0.25% crystal violet in 25%
methanol, washed, and air-dried. 
9. Immunoblotting
Whole cell extraction was performed using RIPA buffer
supplemented with protease inhibitors. 
Samples were denatured in sodium dodecyl sulfate (SDS)
sample buffer. Total proteins were separated by loading 20
µg of total cell lysate onto a denaturing SDS-polyacrylamide
gel and transferred onto a polyvinylidene difluoride mem-
brane. Membranes were blocked with 3% non-fat dry milk
in phosphate-buffered saline containing 0.1% Triton X-100,
followed by incubation with primary antibodies that recog-
nize anti-Ero1l (Santa Cruz Biotechnology, Dallas, TX), anti-
Akt, anti–phospho-Akt (Ser473), anti-JNK, anti–phospho-JNK
(Thr183/Tyr185), anti–glyceraldehyde 3-phosphate dehy-
drogenase, and actin (Cell Signaling, Danvers, MD). Second-
ary antibody conjugated to horseradish peroxidase (Vector
Laboratories Inc.) was used for detection of primary antibod-
ies, and enzymatic signals were visualized using a chemilu-
minescence kit (Thermo Scientific). Western blots were
quantitated using ImageJ software.
10. Statistical analysis for survival data
The BRB-Array Tools system was used for analysis of the
microarray data. Statistical analyses were primarily per-
formed using PASW ver. 17.0 (SSPS Inc., Chicago, IL), and
graphical interpretations were generated with GraphPad
Prism5 (GraphPad Software, San Diego, CA). Differences 
between groups were analyzed using t test and chi-square
test, and Kaplan-Meier plots and log-rank test were used for
estimation of patient survival. A p-value of less than 0.05 was
considered statistically significant, and all tests were two-
tailed.
Results
1. Prognostic significance of ERO1L expression in gastric
cancer patients 
In a previous study, we reported on the important role of
thioredoxin (TXN) in gastric cancer. Approximately 7,000
genes were significantly correlated with TXN according to
the bioinformatics in-trans correlation analysis of TXN 
expression using whole mRNA-expressing genes (p < 0.001).
In-trans correlation analysis between TXN family genes
Table 2. Protein expression of ERO1L protein in gastric cancers
Characteristic ERO1L high-expression ERO1L low-expression p-value
Total (n=231) 107 (46) 124 (54)
Histological type
Intestinal type (n=80) 42 (53) 38 (47) 0.170
Diffuse type (n=151) 65 (43) 86 (57)
Stage
Stage I/II (n=150) 63 (42) 87 (58) 0.073
Stage III/IV (n=81) 44 (54) 37 (46)
Values are presented as number (%). ERO1L, endoplasmic reticulum oxidoreduction 1-.
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Fig. 3. Kaplan-Meier plot of recurrence-free survival (RFS) and overall survival (OS) according to gene expression. (A) Gene 
expression was measured using quantitative reverse transcription polymerase chain reaction in 56 stage III gastric cancer patients.
(B) Gene expression was measured using immunohistochemical staining analysis in 231 gastric cancer patients divided into two
groups according to their gene expression levels. ERO1L, endoplasmic reticulum oxidoreduction 1-.
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showed positive correlation of ERO1L with TXN (r=0.586, 
p < 0.001) (Fig. 1), suggesting that tumors were in a relatively
high hypoxic state. ERO1L and TXN family member genes
were highly expressed under hypoxic conditions in gastric
cancer cell lines (AGS, SNU1, and NCI-N87) (Fig. 2).
To determine the association between ERO1L gene expres-
sion and prognosis among patients with the same stage of
cancer, 56 stage III patients were randomly selected for qRT-
PCR analysis (Table 1). The median follow-up duration after
curative resection was 83.8 months. By the last follow-up
visit, 31 patients had experienced recurrence, and 22 patients
had died of gastric cancer. The patients were divided into
high or low expression groups according to ERO1L expres-
sion level. Recurrence-free survival (RFS) and OS were ana-
lyzed between the two groups. Expression of ERO1L in stage
III gastric cancer patients showed a significant association
with RFS (p=0.001) and OS (p=0.010) (Fig. 3A). 
To examine the relationship between ERO1L expression
and clinicopathological features, immunohistochemical
assay analysis of ERO1L was performed in 231 gastric cancer
specimens. ERO1L was overexpressed in approximately 46%
of cancer tissues regardless of histological type and TNM
stage (Table 2). There was no association between histologi-
cal cell type or tumor stage and ERO1L expression level
(p=0.170 or p=0.073, respectively). Representative immuno-
histochemical staining results are shown in Fig. 4. RFS and
OS were analyzed between the two groups (ERO1L-high and
ERO1L-low), as shown in the immunohistochemical staining
results (Fig. 3B). ERO1L protein expression influenced OS
(p=0.006), whereas ERO1L protein expression did not show
a significant association with RFS (p=0.070). Taken together,
these data indicate that high ERO1L expression was predic-
tive of a poor prognosis for gastric cancer patients.
2. ERO1L expressed in human gastric cancer cell lines
We next evaluated whether or not human gastric cancer
cell lines express ERO1L and thus their utility in assessing
the potential function of ERO1L protein. The mRNA expres-
sion level of ERO1L was measured by qRT-PCR analysis
(Fig. 5A), and Western blots analysis confirmed EOR1L pro-
tein expression in gastric cancer cell lines (Fig. 5B). Strong
EOR1L expression was observed in primary and metastatic
gastric carcinoma cells (AGS, established from a primary
tumor; MKN45, metastatic). These results suggest that at
Fig. 4. Representative images of endoplasmic reticulum oxidoreduction 1- (ERO1L) protein expression in gastric cancer. High im-
munohistochemical staining of ERO1L in cytoplasm of gastric cancer (left, 40; middle, 100; right, 200).
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Fig. 5. Endoplasmic reticulum oxidoreduction 1-
(ERO1L) expression in gastric cancer cell lines. (A) ERO1L
mRNA levels were assessed using quantitative real-time
reverse transcription polymerase chain reaction. Expres-
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(B) ERO1L protein levels were analyzed using immun-
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least a subset of well-credentialed gastric cancer cell lines 
retains ERO1L expression, thereby allowing for further func-
tional characterization. As a functional study, we selected
two gastric cancer cell lines (AGS and NCI-N87) that demon-
strated ERO1L expression by qRT-PCR and microarray
analyses.
3. ERO1L knockdown reduces cell proliferation in gastric
cancer cells
The biological function of ERO1L in gastric cancer is still
unknown. To examine the potential role of ERO1L in gastric
cancer cells, we first knocked down ERO1L in gastric cancer
cell lines (AGS and NCI-N87) using ERO1L-specific shRNAs.
The two most efficiently knocked down cells for each cell
type were selected to further examine phenotypic changes
arising from ERO1L expression. Knockdown yielded > 60%
reduction of EOR1L mRNA and protein expression (Fig. 6).
We analyzed the effects of ERO1L-deficient gastric cancer
cells (AGS, shERO1L.C02 and C06; NCI-N87, shERO1L.C04
and C06) compared with shNonTarget vector-infected con-
trol cells (AGS, shNon.C03 and C06; NCI-N87, shNon.C01
and C02). Proliferation was tested in short-term proliferative
impact (WST-1 assay) and long-term proliferative ability
(colony formation assay). ERO1L shRNA-mediated knock-
down resulted in significantly reduced growth of gastric can-
cer cell lines (p < 0.001) (Fig. 7A). Similar results were also
observed for colony formation, which was also significantly
inhibited (p < 0.001) in shERO1L cells compared with shNon-
Target cells (Fig. 7B).
4. ERO1L expression is associated with gastric cancer cell
invasiveness and migration
Next, we tested whether or not ERO1L expression is 
involved in progression of gastric cancer to metastatic dis-
ease, especially in late tumorigenesis, including migration
and invasion.
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For this, because directional migration is an important pre-
requisite of cancer cell invasion, we evaluated the ability of
ERO1L expression cells to migrate. Using Boyden chambers,
we measured migration of ERO1L-deficient gastric cancer
cells (AGS, shERO1L.C02 and C06; NCI-N87, shERO1L.C04
and C06). ERO1L shRNA-mediated knockdown significantly
reduced numbers of migratory cells (p < 0.01) (Fig. 8A). To
examine whether or not reduction of cell migration could 
potentially inhibit invasiveness of these cells, invasion of
ERO1L-deficient gastric cancer cells (AGS, shERO1L.C02 and
C06; NCI-N87, shERO1L.C04 and C06) into the matrigel
membrane was measured by Boyden chamber assay. ERO1L
shRNA-mediated knockdown significantly reduced the
numbers of invasive cells (p < 0.001) (Fig. 8B). Intriguingly,
these data indicate that ERO1L shRNA-mediated knock-
down reduced migration and invasion of AGS and NCI-N87
cells (AGS, shERO1L.C02 and C06; NCI-N87, shERO1L.C04
and C06) compared with the control (AGS, shNon.C03 and
C06; NCI-N87, shNon.C01 and C02). 
5. ERO1L is related to chemoresistance in gastric cancer
We further examined whether or not ERO1L plays a role
in chemoresistance in gastric cancer cells. After silencing
ERO1L expression with specific shRNA, cell viability assays
were performed in gastric cancer cells using a panel of
chemotherapy agents, which were commonly used in treat-
ment of gastric cancer, including an anti-metabolite (5-FU)
and a microtubule stabilizer (paclitaxel). Interestingly, when
ERO1L expression was silenced, AGS and NCI-N87 cells
(AGS, shERO1L.C02 and C06; NCI-N87, shERO1L.C04 and
C06) became more sensitive to 5-FU and paclitaxel, suggest-
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ing that ERO1L might account for the resistance of gastric
cancer cells to 5-FU and paclitaxel (Fig. 9). 
6. Down-regulation of AKT and JNK signaling by ERO1L
knockdown
Several pathways were investigated in order to elucidate
the molecular mechanism of ERO1L knockdown-mediated
inhibition of gastric cancer proliferation, migration, invasion,
and chemoresistance. Several important proteins were dif-
ferentially expressed between ERO1L-deficient gastric cancer
cells (AGS, shERO1L.C02 and C06; NCI-N87, shERO1L.C04
and C06) and shNonTarget vector–infected control cells
(AGS, shNon.C03 and C06; NCI-N87, shNon.C01 and C02). 
Akt phosphorylation at Ser473 and JNK phosphorylation
at Thr183/Tyr185 were surprisingly reduced in ERO1L-
deficient gastric cancer cells (AGS, shERO1L.C02 and C06;
NCI-N87, shERO1L.C04 and C06) (Fig. 10).
Discussion
We first obtained ERO1L expression data from tumor tis-
sue samples using qRT-PCR and immunohistochemical
assay. Stage III patients who underwent curative gastrec-
tomy were significantly different from patients showing dif-
ferent ERO1L expression levels, as determined by qRT-PCR
(Fig. 3A). Similar results were obtained from immunohisto-
chemical assay analysis of gastric cancer specimens (Fig. 3B).
Gastric cancer patients showing high ERO1L expression 
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received a definitively poor prognosis. Thus, intensive treat-
ment and planning of post-adjuvant treatment is required for
these patients. 
ERO1L plays a pivotal role in VEGF production through
disulfide bond formation by protein disulfide isomerase
within VEGF protein, suggesting that ERO1L affects tumor
growth through angiogenic signaling pathways. Expression
of ERO1L is significantly associated with an aggressive
breast cancer phenotype, suggesting the potential of ERO1L
as a new prognostic marker for breast cancer after surgery.
However, how ERO1L expression is regulated under 
hypoxia and within tumor cells should be determined. More
importantly, the precise mechanism of tumor cell growth
should be elucidated. 
In this study, we demonstrated that ERO1L-deficient gas-
tric cancer cells (AGS, shERO1L.C02 and C06; NCI-N87,
shERO1L.C04 and C06) could effectively suppress cell pro-
liferation and inhibit colony formation, migration, invasive-
ness, and chemoresistance (Figs. 7-9). According to our
results, ERO1L is an attractive therapeutic target for the treat-
ment of gastric cancer. The current results demonstrate that
inhibition of the phosphoinositide 3-kinase (PI3K) and JNK
mitogen-activated protein kinase (MAPK) signaling path-
ways plays an important role in cell cycle transition, prolif-
eration, and metastasis. Furthermore, dual inhibition of the
PI3K and MAPK pathways has synergy in lung cancers that
are unresponsive to single PI3K inhibition. Akt (also called
PKB) is an important downstream effector of PI3K, and acti-
vated Akt translocates to the cytoplasm and nucleus to acti-
vate downstream targets involved in survival, proliferation,
cell cycle progression, migration, and angiogenesis [19].
Phosphorylation of Akt at Ser473 is increased in poorly dif-
ferentiated prostate cancer cells [20] and is a good predictor
of poor clinical outcome in cancer patients [21]. The stress-
activated protein kinase pathway, JNK, alternatively referred
to as SAPK/JNK, also plays an important role in control of
cell proliferation in a wide variety of cell types. Reduced 
activation of JNK could be beneficial in controlling growth
in tumors expressing over-activated JNK [22]. Activated JNK
may act as an oncoprotein due to its ability to activate the
transcription factor component c-JUN or inactivate the pro-
apoptotic protein BAD [23]. Thus, reduced activation of JNK
could be beneficial for controlling growth of tumors express-
ing over-activated JNK. Together, these results indicate that
ERO1L expression could potentially modulate activity of the
Akt and JNK pathway in gastric cancer cells.
The results of our study show that ERO1L-deficient gastric
cancer cells (AGS, shERO1L.C02 and C06; NCI-N87,
shERO1L.C04 and C06) led to reduction of Akt phosphory-
lation at Ser473, as expected, due to reduction of Akt activa-
tion. Likewise, shRNA-mediated ERO1L knockdown led to
decreased phosphorylation of JNK at Thr183/Tyr185. Taken
together, inhibition of the Akt and JNK pathways by shRNA-
mediated ERO1L knockdown in gastric cancer cells points to
a potential oncogenic role for ERO1L in gastric cancer.
Conclusion
High expression of ERO1L is implicated in gastric cancer,
particularly in tumors with poor-prognostic features. ERO1L
is a promising prognostic marker of gastric cancer, and per-
sonalized adjuvant treatment based on ERO1L expression
levels would be an effective practice for treatment of gastric
cancer. Administration of the appropriate drug improves
clinical outcomes and decreases toxicity.
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